Auteurs

Dr. Manja Epping

Associé

Read More

Evelyne Friedel

Associé

Read More

Judith Krens

Associé

Read More

Matthew Royle, Ph.D.

Associé

Read More
Auteurs

Dr. Manja Epping

Associé

Read More

Evelyne Friedel

Associé

Read More

Judith Krens

Associé

Read More

Matthew Royle, Ph.D.

Associé

Read More

30 mai 2019 |

Recent legislative developments affecting biologics and biosimilars

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. Recently, a flurry of proposed legislation has threatened to drastically alter the US regulation of and policies on wide ranging topics such as drug pricing, mandatory licensing, patent thickets, and the availability of post-grant proceedings.

In session 2 of this series we focus on key factors decision makers need to be aware of when considering currently pending legislation, including:

  • Key provisions of proposed legislation
  • European perspectives and approaches to similar issues

View session 1


Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Sciences de la vie et Santé

Biologics and biosimilars litigation update

25 novembre 2020
Quick read

par plusieurs auteurs

Cliquer ici pour en savoir plus
centrifuge-machine
Sciences de la vie et Santé

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

27 juillet 2020
QUICK READ

par plusieurs auteurs

Cliquer ici pour en savoir plus
woman-with-scientific-model
Sciences de la vie et Santé

Everything biologic and biosimilar in-house counsel need to know about COVID-19

29 avril 2020

par plusieurs auteurs

Cliquer ici pour en savoir plus

Événements connexes